Drug Combination Shows Promise for Rhabdomyosarcoma, but Can It Get to Clinical Trials? - Cancer Currents Blog

The latest from the NCI Cancer Currents blog

Having trouble viewing this email? View it as a Web page.

Drug Combination Shows Promise for Rhabdomyosarcoma, but Can It Get to Clinical Trials? 12/09/2022 An NCI study in mice has identified a potential new drug combination for children with rhabdomyosarcoma. But one of the drugs, ganitumab, is no longer being made. The NCI researchers who led the study are exploring options for continuing their work. You are subscribed to the latest posts from Cancer Currents: An NCI Cancer Research Blog from the National Cancer Institute. Update your subscriptions.

Stay Connected with the National Cancer Institute
Chat with us: LiveHelp  Call us: 1-800-4-CANCER (1-800-422-6237) SUBSCRIBER SERVICES: Manage Subscriptions  |  Help

 

This email was sent to myhcistech.healthnews360@blogger.com using GovDelivery Communications Cloud on behalf of: National Cancer Institute · BG 9609 MSC 9760 · 9609 Medical Center Drive · Bethesda, MD 20892